The Results of Interferon-Alpha Treatment in Behcet Uveitis

Eser Öztürk H., Süllü Y.

OCULAR IMMUNOLOGY AND INFLAMMATION, cilt.28, sa.3, ss.498-504, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/09273948.2019.1587473
  • Dergi Adı: OCULAR IMMUNOLOGY AND INFLAMMATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.498-504
  • Anahtar Kelimeler: Behcet disease, Behcet uveitis, interferon-alpha, CYSTOID MACULAR EDEMA, LONG-TERM EFFICACY, THERAPY, DISEASE, NEOVASCULARIZATION, SAFETY
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Purpose: To assess the efficacy and tolerability of interferon alpha (IFN-alpha) treatment in patients with refractory Behcet uveitis (BU). Methods: The patients with BU who were treated with subcutaneous IFN-alpha were divided into groups according to treatment response. Demographic features, best corrected visual acuity (BCVA), central macular thickness (CMT) value, and fluorescein angiography (FA) scores were compared between the groups. Results: Twenty-one (84%) of the 25 patients responded to IFN-alpha treatment. Active inflammation resolved at the first month's visit in all patients. The improvement in mean BCVA and CMT achieved at the first month's visit in all groups; however, the improvement in mean CMT in the non-responder group could not be maintained at the last visit. Main FA score significantly decreased in both the complete and partial remission group; however, it decreased minimally in the non-responder group. Conclusion: IFN-alpha seems an effective and safe treatment option in the management of refractory BU.